WordNet

the 1st letter of the Roman alphabet (同)a
the blood group whose red cells carry the A antigen (同)type_A, group A
a class of proteins produced in lymph tissue in vertebrates and that function as antibodies in the immune response (同)Ig, immune serum globulin, immune gamma globulin, immune_globulin
inflammation of the liver caused by a virus or a toxin

PrepTutorEJDIC

answer / ampere
肝[臓]炎
arsenicの化学記号

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. A型肝炎ウイルスワクチンと曝露後の予防 hepatitis a virus vaccination and postexposure prophylaxis
2. 小児におけるA型肝炎ウイルス感染の概要 overview of hepatitis a virus infection in children
3. 免疫グロブリンの使用における一般原則 general principles in the use of immune globulin
4. 原発性免疫不全症における免疫グロブリン療法 immune globulin therapy in primary immunodeficiency
5. 成人におけるA型肝炎ウイルス感染の概要 overview of hepatitis a virus infection in adults

English Journal

Case report of a transfusion-associated hepatitis A infection.

Hughes JA1, Fontaine MJ, Gonzalez CL, Layon AG, Goodnough LT, Galel SA.Author information 1Department of Pathology, Stanford University School of Medicine, Stanford, California.AbstractBACKGROUND: Documented transfusion-associated hepatitis A (TAHA) is rare, and blood donors in the United States are not routinely screened for this infection. We report a case of TAHA associated with a donation made 8 days after a donor returned from a trip to South America.
Transfusion.Transfusion.2014 Apr 1. doi: 10.1111/trf.12648. [Epub ahead of print]
BACKGROUND: Documented transfusion-associated hepatitis A (TAHA) is rare, and blood donors in the United States are not routinely screened for this infection. We report a case of TAHA associated with a donation made 8 days after a donor returned from a trip to South America.STUDY DESIGN AND METHODS:
PMID 24689888

Robustness of nanofiltration for increasing the viral safety margin of biological products.

Caballero S1, Diez JM2, Belda FJ2, Otegui M2, Herring S3, Roth NJ4, Lee D4, Gajardo R2, Jorquera JI2.Author information 1Research and Development Area, Biologics Industrial Group, Grifols, Parets del Vallès, Barcelona, Spain. Electronic address: santiago.caballero@grifols.com.2Research and Development Area, Biologics Industrial Group, Grifols, Parets del Vallès, Barcelona, Spain.3Research and Development Area, Biologics Industrial Group, Grifols, Los Angeles, CA, USA.4Research and Development Area, Biologics Industrial Group, Grifols, Research Triangle Park, NC, USA.AbstractIn this study, the virus-removal capacity of nanofiltration was assessed using validated laboratory scale models on a wide range of viruses (pseudorabies virus; human immunodeficiency virus; bovine viral diarrhea virus; West Nile virus; hepatitis A virus; murine encephalomyocarditis virus; and porcine parvovirus) with sizes from 18 nm to 200 nm and applying the different process conditions existing in a number of Grifols' plasma-derived manufacturing processes (thrombin, α1-proteinase inhibitor, Factor IX, antithrombin, plasmin, intravenous immunoglobulin, and fibrinogen). Spiking experiments (n = 133) were performed in process intermediate products, and removal was subsequently determined by infectivity titration. Reduction Factor (RF) was calculated by comparing the virus load before and after nanofiltration under each product purification condition. In all experiments, the RFs were close to or greater than 4 log10 (>99.99% of virus elimination). RF values were not significantly affected by the process conditions within the limits assayed (pH, ionic strength, temperature, filtration ratio, and protein concentration). The virus-removal capacity of nanofiltration correlated only with the size of the removed agent. In conclusion, nanofiltration, as used in the manufacturing of several Grifols' products, is consistent, robust, and not significantly affected by process conditions.
Biologicals : journal of the International Association of Biological Standardization.Biologicals.2014 Mar;42(2):79-85. doi: 10.1016/j.biologicals.2013.10.003. Epub 2014 Jan 29.
In this study, the virus-removal capacity of nanofiltration was assessed using validated laboratory scale models on a wide range of viruses (pseudorabies virus; human immunodeficiency virus; bovine viral diarrhea virus; West Nile virus; hepatitis A virus; murine encephalomyocarditis virus; and porci
PMID 24485384

Cross-sectional study of HPV-16 infection in a population-based subsample of Hispanic adults.

Ortiz AP1, Unger ER, Muñoz C, Panicker G, Tortolero-Luna G, Soto-Salgado M, Otero Y, Suárez E, Pérez CM.Author information 1Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico.AbstractOBJECTIVE: This study aimed to estimate the prevalence and correlates of seropositivity to human papillomavirus (HPV)-16 in a subsample of adults who participated in the parent study Epidemiology of Hepatitis C in the adult population of Puerto Rico (PR).
BMJ open.BMJ Open.2014 Feb 4;4(2):e004203. doi: 10.1136/bmjopen-2013-004203.
OBJECTIVE: This study aimed to estimate the prevalence and correlates of seropositivity to human papillomavirus (HPV)-16 in a subsample of adults who participated in the parent study Epidemiology of Hepatitis C in the adult population of Puerto Rico (PR).SETTING: The parent study was a population-ba
PMID 24496698